Alkermes Plc Ownership
| ALKS Stock | USD 26.66 2.56 8.76% |
Shares in Circulation | First Issued 1991-06-30 | Previous Quarter 166.6 M | Current Value 168.7 M | Avarage Shares Outstanding 99.8 M | Quarterly Volatility 51.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alkermes Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. Alkermes Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Alkermes Plc was presently reported as 9.17. The company had not issued any dividends in recent years. Alkermes Plc had 2:1 split on the 15th of May 2000. Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Alkermes Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2211 people. For more info on Alkermes Plc please contact Richard Pops at 353 1 772 8000 or go to https://www.alkermes.com.Besides selling stocks to institutional investors, Alkermes Plc also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Alkermes Plc's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Alkermes Plc's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Alkermes Plc Quarterly Liabilities And Stockholders Equity |
|
Alkermes Plc Insider Trades History
Only 1.49% of Alkermes Plc are currently held by insiders. Unlike Alkermes Plc's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Alkermes Plc's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Alkermes Plc's insider trades
Alkermes Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alkermes Plc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alkermes Plc backward and forwards among themselves. Alkermes Plc's institutional investor refers to the entity that pools money to purchase Alkermes Plc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-03-31 | 3 M | Primecap Management Company | 2025-03-31 | 3 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 3 M | Venbio Select Advisor Llc | 2025-03-31 | 2.5 M | Loomis, Sayles & Company Lp | 2025-03-31 | 2.4 M | Holocene Advisors, Lp | 2025-03-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 2.2 M | Charles Schwab Investment Management Inc | 2025-03-31 | 2 M | Nuveen, Llc | 2025-03-31 | 2 M | Blackrock Inc | 2025-03-31 | 27.4 M | Vanguard Group Inc | 2025-03-31 | 18.2 M |
Alkermes Plc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alkermes Plc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alkermes Plc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alkermes Plc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alkermes Plc Outstanding Bonds
Alkermes Plc issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alkermes Plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alkermes bonds can be classified according to their maturity, which is the date when Alkermes Plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Alkermes Plc Corporate Filings
8K | 21st of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 10th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of May 2025 Other Reports | ViewVerify | |
| 12th of May 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.